Journal article icon

Journal article

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Abstract:

The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and safety profile for two different dosing regimens of barasertib, a selective inhibitor of Aurora B Kinase. In this Phase I trial, patients with advanced solid malignancies were treated with escalating doses of barasertib, administered as either a 48-h continuous infusion or as two 2-h infusions on consecutive days, both every 14 days of a 28-day cycle. Thirty-five patients were treated. The MTDs w...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1007/s10637-012-9825-7

Authors


Schwartz, GK More by this author
Carvajal, RD More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Stockman, PK More by this author
Expand authors...
Journal:
Investigational new drugs
Volume:
31
Issue:
2
Pages:
370-380
Publication date:
2013-04-05
DOI:
EISSN:
1573-0646
ISSN:
0167-6997
URN:
uuid:4bdd8218-f1a3-497a-a333-d7f60cdf3106
Source identifiers:
396409
Local pid:
pubs:396409

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP